Henlius Biotech Files for Fourth Biosimilar IND in China

Henlius Biotechnology, a California-China biopharma that is developing biosimilar/bio-better drugs for the China market, filed an IND with the CFDA to begin clinical trials of its fourth molecule, a VEGF antibody. Although the CFDA has not defined a regulatory pathway for biosimilars, Henlius is adhering closely to international standards. Together with its major sponsor, Fosun Pharma, Henlius plans to market its drugs in China while finding partners for other parts of the world. More details.... Stock Symbols: (SHA: 600196; HK: 2196) Share this with colleagues: // //